Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of
herpetic keratitis and shows potential for effectiveness against other viral ocular
infections. The majority of adenoviral conjunctivitis will resolve without damaging vision,
however, the investigators have no way to determine which cases will progress to ocular
complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the
efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral
conjunctivitis.